CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- 144 Insider Sale of Securities
- 424B5 Offering Prospectus
- 10-Q Report Quarterly Report
- 4 Planned sale Director sold 9,750 shares at $44.22 ($431,145)
- 8-K Event Results of operations
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Research Officer sold 9,100 shares at $39.09 ($355,719)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 8,000 shares at $41.07 ($328,560)
- 4 Planned sale Director sold 32,750 shares at an average $41.29 ($1,352,130)
- 4 Planned sale SVP, CHIEF ACCOUNTING OFFICER sold 21,977 shares at $41.07 ($902,595)
- 4 Open-market sale CHIEF COMMERCIAL OFFICER sold 7,215 shares at $41.93 ($302,516)
- 4 Grant or award Chief Research Officer acquired 14,000 shares (grant or award)
- 4 Planned sale CHIEF EXECUTIVE OFFICER sold 64,000 shares at an average $41.09 ($2,629,975)
- 4 Planned sale Chief Legal Officer and GC sold 51,500 shares at an average $41.29 ($2,126,452)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 8,327 shares at an average $41.91 ($348,974)
Page 5 of 65 · 1,286 filings